Pulse Biosciences Reports Highly Positive 12-Month Clinical Data for nPulse Cardiac Catheter System
Summary
Pulse Biosciences announced updated, highly positive 12-month clinical data from its first-in-human study of the nPulse Cardiac Catheter System for atrial fibrillation, demonstrating strong efficacy and safety.
Key Events
-
Sustained High Procedural Success
The nPulse Cardiac Catheter System achieved 100% procedural success of evaluable patients by Holter at 6 months (95/95) and 96% at one year (51/53).
-
Strong Freedom from Atrial Arrhythmias
The study reported a sustained 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year.
-
Efficient Procedural Performance
The system demonstrated efficient performance with an average total procedure time of 60.2 minutes and left atrial dwell time of 18.6 minutes.
-
Favorable Safety Profile
A low serious adverse event rate of 1.7% (3/177 subjects) was maintained across the total cohort.
Analysis
This 8-K formalizes and provides detailed, positive clinical outcomes for Pulse Biosciences' nPulse Cardiac Catheter System, building on prior disclosures and a Reuters news report from the same day. The sustained high procedural success rates at both 6 and 12 months, coupled with a low serious adverse event rate, significantly de-risk the product's development and enhance its commercial prospects. These results are crucial for advancing regulatory approvals and positioning the nPulse system as a competitive treatment for atrial fibrillation. Investors should monitor further regulatory progress and commercialization timelines.
At the time of this filing, PLSE was trading at $23.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $12.56 to $26.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.